CAS: 11006-76-1; Virginiamycin Complex

该化合物是一种主要用于兽医,特别是牲畜的抗生素,是一种由两种成分组成的复杂混合物,即处女膜素M1和处女膜素S1,通过细菌发酵产生,这种药物具有广泛的抗微生物活动,特别是抗克菌性细菌,有效抑制蛋白合成.弗吉尼亚菌经常被用作动物饲料的生长促进剂,提高了饲料效率和重量增加.此外,该药物在动物某些感染的治疗中也有应用.该化合物以其在哺乳动物中的低毒性而著称,因此在兽医应用中它是一种首选.然而,对抗生素抗药性及其可能对人类健康的影响的关切已导致对其使用进行更多的检查和管制.与许多抗生素一样,谨慎管理对于减轻抗药性发展的风险至关重要.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-7255989-B1
    优先权日:1999-11-29
    标 题:Method for obtaining nucleic acids from an environment sample, resulting nucleic acids and use in synthesis of novel compounds
    发明人:JEANNIN PASCALE; PERNODET JEAN-LUC; GUERINEAU MICHEL; SIMONET PASCAL; COURTOIS SOPHIE; CAPPELLANO CAMELA; FRANCOU FRANCOIS; RAYNAL ALAIN; BALL MARIA; SEZONOV GUENNADI; TUPHILE KARINE; FROSTEGARD ASA
    权利人:AVENTIS PHARMA SA
    摘要:The invention concerns a method for preparing nucleic acids from an environment sample, more particularly a method for obtaining a library of nucleic acids from a sample. The invention also concerns nucleic acids of nucleic acid libraries obtained by said method their use in the synthesis of novel compounds, in particular novel compounds of therapeutic interest. The invent further concerns novel means used in the method for obtaining said nucleic acids, such as novel vectors and novel processes for preparing such vectors or recombinant host cells containing said nucleic acid. Finally, the invention concerns methods for detecting a nucleic acid of interest within a library of nucleic acids resulting from said method, and nucleic acids detected by said method and polypeptides encoded by said nucleic acids.

    专利号:US-12115231-B2
    优先权日:2015-05-04
    标题 :Ultrasmall nanoparticles and methods of making and using same
    发明人:WIESNER ULRICH B; MA KAI; MENDOZA CARLIE
    权利人:UNIV CORNELL
    摘要:An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.

    专利号:US-2008311631-A1
    优先权日:2004-06-04
    标题 :Biosynthetic Production of 4-Amino 4-Deoxychorismate (Adc) and [3R,4R]-4-Amino-3-Hydroxycyclohexa-1,5-Diene-1-Carboxylic Acid (3,4-Cha)
    发明人:WUBBOLTS MARCEL GERHARDUS; BOVENBERG ROELOF ARY LANS; SPRENGER GEORG; BONGAERTS JOHANNES JOSEF; KOZAK STEFAN; MULLER MICHAEL; LORBACH VOLKER
    权利人:WUBBOLTS MARCEL GERHARDUS; BOVENBERG ROELOF ARY LANS; SPRENGER GEORG; BONGAERTS JOHANNES JOSEF; KOZAK STEFAN; MULLER MICHAEL; LORBACH VOLKER
    摘要:The invention relates to a process for the biosynthetic production of 4-amino-4-deoxychorismate (ADC) performed fermentatively in vivo with a 4-amino-4-deoxychorismate synthase, preferably a PabAB bipartite protein (which may be a fusion protein), at an increased level of activity, thereby obtaining a broth comprising ADC and 4-amino-4-deoxyprephenate (ADP), that are recovered. The invention also relates to a further process of converting the ADP into p-aminophenylalanine. The invention, moreover relates to biosynthetic production of [3R,4R]-4-amino-3-hydroxycyclohexa-1,5-diene-1-carboxylic acid (3,4-CHA), by concerted action of such 4-amino-4-deoxychorismate synthase and of an enzyme capable of converting isochorismate into [5S,6S]-5,6 dihydroxycyclohexa-1,3-diene-1-carboxylic acid (2,3-CHD), preferably a phenazine biosynthesis protein PhzD, including recovery of 3,4-CHA. The invention also relates to expression vectors and host cells for use in any of such processes. The invention further relates to the use of 3,4-CHA as a catalytically active product, in particular as a chiral catalyst. And the invention finally relates to synthesis of oseltamivir phosphate from 3,4-CHA.

    专利号:US-7510852-B2
    优先权日:2002-10-18
    标题:Biosynthetic genes and host cells for the synthesis of polyketide antibiotics and method of use
    发明人:ROYER MONIQUE; GABRIEL DEAN W; FRUTOS ROGER; ROTT PHILIPPE
    权利人:CIRAD; UNIV FLORIDA
    摘要:Three gene clusters that together encode albicidin biosynthesis, the complete gene DNA sequences, and the deduced protein sequences for the enzymes and methods for using the DNA sequences are disclosed and discussed as well as methods for plant protection and creating new antibiotics. The novel Albicidin family of antibiotics is disclosed and their structure deduced.

    专利号:US-7579167-B2
    优先权日:2002-10-08
    标题:Polypeptides involved in the biosynthesis of spiramycins, nucleotide sequences encoding these polypeptides and applications thereof
    发明人:BLONDELET-ROUAULT MARIE-HELENE; DOMINGUEZ HELENE; DARBON-RONGERE EMMANUELLE; GERBAUD CLAUDE; GONDRAN ANNE; KARRAY FATMA; LACROIX PATRICIA; OESTREICHER-MERMET-BOUVIER NATHALIE; JEAN-LUC PERNODET; TUPHILE KARINE
    权利人:AVENTIS PHARMA S; CENTRE NAT RECH SCIENT
    摘要:The present invention relates to the isolation and identification of novel genes of the biosynthetic pathway for spiramycins and to novel polypeptides involved in this biosynthesis. The invention also relates to a method for producing these polypeptides. It also relates to the use of these genes for the purpose of increasing the levels of production and the purity of the spiramycin produced. The invention relates in particular to a microorganism which produces spiramycin I but which does not produce spiramycin II and III, and to the use of such a microorganism. The invention also relates to the use of the genes of the biosynthetic pathway for spiramycins for constructing mutants which can lead to the synthesis of novel antibiotics or to derived forms of spiramycins. The invention also relates to the molecules produced through the expression of these genes and to pharmacologically active compositions of a molecule produced through the expression of such genes.

    专利号:US-9938390-B2
    优先权日:2012-11-26
    标 题:Method for the preparation of macroporous particles and macroporous microclusters
    发明人:STORTI GIUSEPPE; MORBIDELLI MASSIMO; SOOS MIROSLAV; LAMPROU ALEXANDROS; BRAND BASTIAN
    权利人:ETH ZUERICH
    摘要:A method for producing macro porous micro-clusters is proposed comprising at least the following individual steps in given order: a) synthesis of dispersed cross-linked polymeric latex primary particles starting from at least one monomer or oligomer using emulsion polymerization; b) swelling of the primary particles with a liquid comprising at least an additional charge of monomer and/or oligomer and a cross-linker, optionally further comprising functionalization agents; c) destabilization by increase of ionic strength (by adding a salt and/or acid and/or base) in a combination with application of shear, both being above the gel formation boundary of the phase diagram, until agglomerates composed of primary particles of the desired size are formed; d) polymerization of the agglomerates to form the macro porous micro-clusters. Furthermore the invention to relates to correspondingly produced micro-clusters and uses of such micro-clusters in particular for chromatographic purposes.
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Mast Y, Guezguez J, Handel F, Schinko E. A Complex Signaling Cascade Governs Pristinamycin Biosynthesis in Streptomyces pristinaespiralis. Appl Environ Microbiol. 2015 Oct;81(19):6621-36. doi: 10.1128/AEM.00728-15. Epub 2015 Jul 17.
    2: Cooper EC, Curtis N, Cranswick N, Gwee A. Pristinamycin: old drug, new tricks? J Antimicrob Chemother. 2014 Sep;69(9):2319-25. doi: 10.1093/jac/dku167. Epub 2014 Jun 2. Review. doi: 10.1016/j.jbiotec.2015.09.010. Epub 2015 Sep 14. [Pristinamycin/Vitamin k antagonists drug interaction: a French pharmacovigilance database study]. Therapie. 2014 Sep-Oct;69(5):391-4. doi: 10.2515/therapie/2014033. Epub 2014 Jul 23. French. doi: 10.1159/000435812. Epub 2015 Jul 22. doi: 10.1007/s00253-015-6638-6. Epub 2015 May 10. doi: 10.1016/j.ijantimicag.2016.01.017. Epub 2016 Mar 12. doi: 10.1128/JB.00045-15. Epub 2015 Apr 13.
    9: Schmutz JL, Trechot P. [Skin rash mimicking pityriasis rosea Gibert secondary to pristinamycin therapy]. Ann Dermatol Venereol. 2014 Apr;141(4):325-6. doi: 10.1016/j.annder.2014.01.001. Epub 2014 Feb 7. French. Russian. Pristinamycin in the treatment of MSSA bone and joint infection. J Antimicrob Chemother. 2016 Apr;71(4):1063-70. doi: 10.1093/jac/dkv457. Epub 2016 Jan 21. doi: 10.1016/j.ymben.2015.02.001. Epub 2015 Feb 20. doi: 10.3797/scipharm.1506-01. Epub 2015 Jul 22.

    合成参考文献


    摘要:Antibiotics Annual., 1(171), 1953/1954
    摘要:Janssen G, et al; J Antibiot (Tokyo) 30 (2): 141-145 (1977)
    摘要:
    摘要:US FDA/Center for Veterinary Medicine; The Green Book - On Line, Active Ingredients. Virginiamycin. Available from, as of June 20, 2012:
    摘要:
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知